Cinnarizine: A Contemporary Review

  • Milind Vasant Kirtane
  • Anita Bhandari
  • Prashant Narang
  • Ravi SantaniEmail author
Original Article


Cinnarizine, is approved for nausea, vomiting, motion sickness, inner ear disorders and is considered as first-line pharmacotherapy for management of vertigo. It acts by anti-vasoconstrictor activity, reducing blood viscosity and reducing nystagmus in labyrinth. Lack of adequate literature on clinical evidence of cinnarizine and its combination (dimenhydrinate) in vertigo management prompted this review. A specific MEDLINE literature search strategy was designed combining Medical Subject Headings, free-text keywords (like cinnarizine and vertigo) using Boolean operators (1970–2016) for clinical studies, clinical reviews and meta-analyses of cinnarizine. Analyses of studies validated cinnarizine’s efficacy in peripheral and central vertigo versus placebo or other therapies, and was well-tolerated by the patients recruited across different studies. Cinnarizine and/ or its combinations are favorable in management of vestibular disorders wherein cinnarizine acts predominantly peripherally on labyrinth and dimenhydrinate acts centrally on vestibular nuclei and associated centers in brainstem. Combination therapy of cinnarizine and/ or its combinations demonstrated a better safety profile than either of the mono-components, offering a viable therapeutic option in vertigo management.


Cinnarizine Vertigo Dimenhydrinate Drug combinations 



Dr. Sonia Philipose (SIRO Clinpharm Pvt. Ltd.) provided editorial support for this manuscript. This work was supported by funding from Janssen India.

Compliance with Ethical Standards

Conflict of interest



Dr. Ravi Santani and Dr. Prashant Narang are employees and/or shareholders of Janssen, India. All authors contributed to the data interpretation and development of the review. All authors met ICMJE criteria and all those who fulfilled those criteria are listed as authors. All authors had access to the study data, provided direction and comments on the manuscript, made the final decision about where to publish these data and approved submission to the journal.


  1. 1.
    Emanuel MB, Will JA (1977) Cinnarizine in the treatment of peripheral vascular disease: mechanisms related to its clinical action. Proc R Soc Med 70:7–12PubMedPubMedCentralGoogle Scholar
  2. 2.
    Soto E, Vega R (2010) Neuropharmacology of vestibular system disorders. Curr Neuropharmacol 8:26–40PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    National formulary of India, fourth edition, 2011. Accessed 17 Oct 2016
  4. 4.
    Drugs Controller General of India. List of approved drug from 01.01.2010 to 31.12.2010. Accessed 17 Oct 2016
  5. 5.
    Oosterveld WJ (1999) Cinnarizine in the vertiginous syndrome. In: Towse G (ed) cinnarizine and the vertiginous syndrome. International Congress and Symposium Series No. 33. Royal Society of Medicine and Academic Press Inc, London, pp 29–37Google Scholar
  6. 6.
    Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. FIN-RACo trial group. Lancet 353:1568–1573PubMedCrossRefGoogle Scholar
  7. 7.
    Di Perri T, Forconi S, Guerrini M, Pasini FL, Del Cipolla R, Rossi C et al (1977) Action of cinnarizine on the hyperviscosity of blood in patients with peripheral obliterative arterial disease. Proc R Soc Med 70:25–28PubMedPubMedCentralGoogle Scholar
  8. 8.
    Van Nueten JM, Janssens WJ (1988) Cerebral antivasoconstrictive effects of flunarizine. Acta Otolaryngol 105:42–49CrossRefGoogle Scholar
  9. 9.
    Dormandy JA, Hoare E, Khattab AH, Arrowsmith DE, Dormandy TL (1973) Prognostic significance of rheological and biochemical findings in patients with intermittent claudication. Br Med J 4:581–583PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    De Clerck F, Beerens M, Thoné F, Borgers M (1981) Effect of flunarizine on the human red cell shape changes and calcium deposition induced by A 23187. Thromb Res 24:1–12PubMedCrossRefGoogle Scholar
  11. 11.
    Cobb S, Coen LW, Gitomer SL, Iles R (1976) Effect of cinnarizine on nystagmus induced by rotation-deceleration. Eye Ear Nose Throat Mon 55:48–30PubMedGoogle Scholar
  12. 12.
    Mangabeira-Albernaz PL, Ganança MM, Novo NF, de Paiva ER (1978) Flunarizine and cinnarizine as vestibular depressants. A statistical study. ORL J Otorhinolaryngol Relat Spec 40:92–100PubMedCrossRefGoogle Scholar
  13. 13.
    Overstall PW, Hazell JW, Johnson AL (1981) Vertigo in the elderly. Age Ageing 10:105–109PubMedCrossRefGoogle Scholar
  14. 14.
    Haasler T, Homann G, Duong Dinh TAD, Jüngling E, Westhofen M, Lückhoff A (2009) Pharmacological modulation of transmitter release by inhibition of pressure-dependent potassium currents in vestibular hair cells. Naunyn Schmiedebergs Arch Pharmacol 380:531–538PubMedCrossRefGoogle Scholar
  15. 15.
    Neuhauser HK, Lempert T (2009) Vertigo: epidemiologic aspects. Semin Neurol 29:473–481PubMedCrossRefGoogle Scholar
  16. 16.
    Abrol R, Nehru VI, Venkatramana Y (2001) Prevalence and etiology of vertigo in adult rural population. Indian J Otolaryngol Head Neck Surg 53:32–36PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Godfraind T, Towse G, Van Nueten J (1982) Cinnarizine: a selective calcium entry blocker. Drugs Today 18:27–42Google Scholar
  18. 18.
    Labuguen RH (2006) Initial evaluation of vertigo. Am Fam Physician 73:244–251PubMedGoogle Scholar
  19. 19.
    Toledo JB, Pisa H, Marchese M (1972) Clinical evaluation of cinnarizine in patients with cerebral circulatory deficiency. Arzneimittelforschung 22:448–451PubMedPubMedCentralGoogle Scholar
  20. 20.
    Fujimoto S, Sasa M, Takaori S, Matsuoka I (1978) Selective effect of cinnarizine on the vestibular nucleus neurons. Arch Otorhinolaryngol 221:37–45PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
  22. 22.
    Castañeda-Hernández G, Vargas-Alvarado Y, Aguirre F, Flores-Murrieta FJ (1993) Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. Arzneimittelforschung 43:539–542PubMedGoogle Scholar
  23. 23.
    Hahn A, Novotný M, Shotekov PM, Cirek Z, Bognar-Steinberg I, Baumann W (2011) Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: a randomized, double-blind, active-controlled, multicentre study. Clin Drug Investig 31:371–383PubMedCrossRefGoogle Scholar
  24. 24.
    Hahn A, Sejna I, Stefflova B, Schwarz M, Baumann W (2008) A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders: a randomized, reference-controlled clinical study. Clin Drug Investig 28:89–99PubMedCrossRefGoogle Scholar
  25. 25.
  26. 26.
    Djelilovic-Vranic J, Alajbegovic A, Tiric-Campara M, Volic A, Sarajlic Z, Osmanagic E et al (2012) Betahistine or cinnarizine for treatment of Meniere’s disease. Med Arch 66:396–398PubMedCrossRefGoogle Scholar
  27. 27.
    Towse G (1980) Cinnarizine-a labyrinthine sedative. J Laryngol Otol 94:1009–1015PubMedCrossRefGoogle Scholar
  28. 28.
    Schremmer D, Bognar-Steinberg I, Baumann W, Pytel J (1999) Efficacy and tolerability of a fixed combination of cinnarizine and dimenhydrinate in treatment of vertigo: analysis of data from five randomised, double-blind clinical studies. Clin Drug Invest 18:355–368CrossRefGoogle Scholar
  29. 29.
    Scholtz A-W, Ilgner J, Loader B, Pritschow BW, Weisshaar G (2016) Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice. Wien Klin Wochenschr 128:341–347PubMedCrossRefGoogle Scholar
  30. 30.
    Scholtz AW, Schwarz M, Baumann W, Kleinfeldt D, Scholtz H-J (2004) Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study. Clin Ther 26:866–877PubMedCrossRefGoogle Scholar
  31. 31.
    Scholtz A-W, Steindl R, Burchardi N, Bognar-Steinberg I, Baumann W (2012) Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study. Clin Drug Investig 32:387–399PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Trkanjec Z, Aleksić-Shibabi A, Demarin V (2007) Pharmacotherapy of vertigo. Rad za Medicinske Znanosti 69–76Google Scholar
  33. 33.
    Whaetley D (1973) Reports from the general practitioner research group; anthistamines and phenothiazine compared in vertigo. Practitioner 211:224–227Google Scholar
  34. 34.
    Teggi R, Gatti O, Sykopetrites V, Quaglieri S, Benazzo M, Bussi M (2014) Association of cinnarizine and betahistine in prophylactic therapy for Ménière’s disease with and without migraine. Acta Otorhinolaryngol Ital 34:349–353PubMedPubMedCentralGoogle Scholar
  35. 35.
    Pianese CP, Hidalgo LOV, González RH, Madrid CE, Ponce JE, Ramírez AM et al (2002) New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study. Otol Neurotol 23:357–363PubMedCrossRefGoogle Scholar
  36. 36.
    Deering RB, Prescott P, Simmons RL, Downey LJ (1986) A double-blind crossover study comparing betahistine and cinnarizine in the treatment of recurrent vertigo in patients in general practice. Curr Med Res Opin 10:209–214PubMedCrossRefGoogle Scholar
  37. 37.
    Hargreaves J (1980) A double-blind placebo controlled study of cinnarizine in the prophylaxis of seasickness. Practitioner 224:547–550PubMedGoogle Scholar
  38. 38.
    Cullen JR, Hall SJ, Allen RH (1989) Effect of betahistine dihydrochloride compared with cinnarizine on induced vestibular nystagmus. Clin Otolaryngol Allied Sci 14:485–487PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Amery WK, Oosterveld WJ (1975) An evaluation of cinnarizine in aged patients with vertiginous complaints-a multicentre trial. Acta Ther 1:39–43Google Scholar
  40. 40.
    Udvarhelyi A (1978) Comparative study of the effect of devincan and stugeron in patients suffering from cerebrovascular diseases treated at medical departments. Ther Hung (English edition) 26:29–32Google Scholar
  41. 41.
    Novotný M, Kostrica R (2002) Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Meniere’s disease: a randomized, double-blind, parallel group clinical study. Int Tinnitus J 8:115–123PubMedPubMedCentralGoogle Scholar
  42. 42.
    Cirek Z, Schwarz M, Baumann W, Novotny M (2005) Efficacy and tolerability of a fixed combination of cinnarizine and dimenhydrinate versus betahistine in the treatment of otogenic vertigo: a double-blind, randomised clinical study. Clin Drug Investig 25:377–389PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Otto V, Fischer B, Schwarz M, Baumann W, Preibisch-Effenberger R (2008) Treatment of vertebrobasilar insufficiency-associated vertigo with a fixed combination of cinnarizine and dimenhydrinate. Int Tinnitus J 14:57–67PubMedPubMedCentralGoogle Scholar
  44. 44.
    Martines F, Agrifoglio M, Bentivegna D, Mucia M, Salvago P, Sireci F et al (2012) Treatment of tinnitus and dizziness associated vertebrobasilar insufficiency with a fixed combination of cinnarizine and dimenhydrinate. Acta Med Mediterr 28:291–296Google Scholar
  45. 45.
    Pytel J, Nagy G, Tóth A, Spellenberg S, Schwarz M, Répassy G (2007) Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: a 4-week, randomized, double-blind, active-and placebo-controlled, parallel-group, outpatient study. Clin Ther 29:84–98PubMedCrossRefGoogle Scholar
  46. 46.
    Novotny M, Kostrica R, Cirek Z (1999) The efficacy of arlevert therapy for vertigo and tinnitus. Int Tinnitus J 5:60–62PubMedGoogle Scholar

Copyright information

© Association of Otolaryngologists of India 2017

Authors and Affiliations

  • Milind Vasant Kirtane
    • 1
  • Anita Bhandari
    • 2
  • Prashant Narang
    • 3
  • Ravi Santani
    • 3
    Email author
  1. 1.Department of OtolaryngologyP.D. Hinduja National Hospital and Medical Research CentreMumbaiIndia
  2. 2.Vertigo and Ear ClinicJaipurIndia
  3. 3.Medical Affairs DepartmentJanssen IndiaMumbaiIndia

Personalised recommendations